

**MYÉLOME
CANADA**



**MYELOMA
CANADA**

Uniquely devoted to the Canadian myeloma community

**New Brunswick Approves Front-Line Funding for Velcade® (bortezomib)
December 3rd 2010**

Effective December 3rd 2010, the New Brunswick Department of Health approved front-line funding for Velcade® (bortezomib) as a combination therapy for the treatment of patients with previously untreated multiple myeloma.

Velcade® will be used in the VMP regimen (i.e. in combination with melphalan and prednisone) for patients who are ineligible for stem cell transplantation. This step ensures patients in New Brunswick have access to a new treatment protocol in the management of multiple myeloma.